Evaluation of the safety and efficacy of daily oral Angelica gigas Nakai (AGN)-INM176 in prostate cancer patients with rising plasma PSA (phase I/II trial). This is an ASCO Meeting Abstract from the ...
Secondary outcomes by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR) treated with enzalutamide (enza) monotherapy (mono): EMBARK post ...
The second annual report from the National Cancer Database (NCDB) of the American College of Surgeons (ACS) documents a substantial rise in medication treatments, such as chemotherapy, immunotherapy, ...
Cribriform-positive morphology was associated with a 3.6-fold higher risk for metastasis in patients with prostate cancer, and radiotherapy with neoadjuvant androgen deprivation therapy (ADT) was ...
Many men with aggressive prostate cancer can experience a high rate of recurrence despite treatment. A new Phase 2 clinical trial at UC Davis Comprehensive Cancer Center unveiled clues as to why these ...
Salvage focal therapy may offer durable localized prostate cancer control for up to 10 years compared with salvage radical prostatectomy for radiorecurrent disease. For patients with localized, biopsy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results